Press Releases

 

Thursday, January 04, 2018

Genelux Announces Gynecologic Oncology Associates/Women’s Cancer Research Foundation as New Site for the Ongoing Phase 2 VIRO-15 Study… more

Wednesday, September 27, 2017

Genelux Initiates Phase 2 Clinical Trial of GL-ONC1 in Recurrent Ovarian Cancer… more

Thursday, July 28, 2016

Genelux Initiates Two Clinical Trials of GL-ONC1 in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institutions… more

Wednesday, May 27, 2015

Genelux Announces Promising Data from Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma… more

Tuesday, May 12, 2015

Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015… more

Wednesday, May 28, 2014

Genelux Appoints George Vandeman and Thomas Zindrick to Board of Directors… more

Thursday, May 15, 2014

Genelux Corporation Announces Former Amgen, Abbott Executives to Succeed Dr. Aladar A. Szalay, as CEO, Chairman of the Board… more

Tuesday, February 11, 2014

Genelux Corporation Appoints John D. Prunty Chief Financial Officer… more

Monday, November 18, 2013

Genelux Corporation’s GL-ONC1 selected by Elsevier among its “Top 10 Oncology Projects to Watch”… more

Thursday, June 27, 2013
Genelux Corporation Appoints Stefan M. Manth, MD, as President & CEO, Genelux Europe…more

Saturday, June 15, 2013
Genelux Presents Abstracts at the 7th International Meeting on Replicating Oncolytic Virus Therapeutics in Quebec…more

Thursday, May 30, 2013
Genelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate…more

Monday, February 11, 2013
Virus Engineered to Express Melanin Offers New Possibilities to Diagnose and Treat Solid Tumor Cancers… more

Thursday, February 5, 2013
First Patient Treated in Genelux Phase I Trial with GL-ONC1 at Memorial Sloan Kettering Cancer Center… more

Thursday, November 1, 2012
Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers…more

Saturday, June 28, 2012
Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients… more

Thursday, June 14, 2012
Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of
GL-ONC1… more

Thursday, May 31, 2012
Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers…more

Wednesday, May 30, 2012
Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, its Oncolytic Virus Lead Product Candidate …more

Thursday, August 4, 2011
Genelux Corporation Appoints Catherine J. Mackey, PhD to Board of Directors… more

Monday, June 6, 2011
Preliminary results of Phase I Clinical Trial involving Intravenous Administration of GL-ONC1 to Patients with Advanced Solid Tumor Cancers presented at ASCO… more

Monday, January 24, 2011
Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive…more

Sunday, November 14, 2010
Genelux Awarded Therapeutic Discovery Project Grant… more